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Defining dose requirement, pharmacokinetics and pharmacodynamics
Clinical anaesthetists administer doses of drugs to obtain various degrees of drug effect. Some anaesthetic drug effects, such as muscle relaxation, are relatively easy to quantitate, whereas others such as anaesthetic depth are much more difficult. Anaesthetic dose requirement can be defined as the dose of drug that produces a defined degree of effect. For example, an EDs0 would represent the dose of a drug that results in 50 per cent of the maximal drug effect, whereas an EDgs is the dose that creates 95 per cent of the maximal drug effect. Alternatively, the dose requirement can be expressed as the dose that results in 50 or 95 per cent of a group of patients reaching a defined drug effect, i.e., no response to a specific stimuli. The dose requirement is determined by two pharmacological processes: pharmacokinercs, which is the relationship between dose and drug plasma concentration and pharmeeodynamics, the relationship between drug plasma concentration and degree of drug effect, Pharmaeokinetics characterizes those physiological or pharmacological processes that govern the resultant drug plasma concentration or "what the body does to the drug." Pharmacodynamics represents the relationship between drug plasma concentration, the drug concentration at the site of action and the actual occurrence of a measurable drug effect. Pharmacodynamics represents "what the drug does to the body."
Basic Terminology
Pharmacokinetics and pharmacodynamics are critically dependant on the appropriate measurement technology. Pharmacokinetic research involves measurement of the drug concentrations in biological fluids. Pharmacodynamic research involves measurement of the degree of drug effect. In pharmacokinetic research, one uses mathematical models to describe the interaction of the body's physiological forces with the drug. Five basic pharmaeokinetic parameters can be used to describe any (:[rug. [1] [2] [3] These include the initial and steady-state distribution volumes, distributional and metabolic clearances and the terminal elimination half-life.
The distribution volume represents the theoretical body space with which the drug has equilibrated. The initial distribution volume generally reflects blood volume and rapidly peffused (vessel-rich) tissues. The initial distribution volume will govern the peak plasma concentrations after a rapid intravenous bolus. The steady-state distribution volume is a global measure of the overall distribution of drug to all of the body tissues. A large steady-state distribution volume indicates that a significant amount of drug has partitioned into the tissues with generally higher tissue concentrations relative to plasma. The small steadystate distribution volume reflects very limited tissue penetration with drug confined to the blood volume and interstitial fluid. Drug clearance is analogous to the clinical concept of ereatinine clearance: the volume of plasma that is completely removed of drug per unit lime. Distributional clearance represents a measure of the rate of drug movement from the initial distribution volume to peripheral tissue compartments. Generally, distributional clearance is governed by blood flow to the tissues and is responsible for the initial rapid decline of the drug plasma concentration after an intravenous bolus. The metabolic clearance of the drug is a reflection of the rate of drug metabolism and elimination from the body. The metabolic clearance can involve both the hepatic metabolism to pharmacologically inactive compounds or the excretion of unchanged drug by the kidney. Distributional clearance reflects movement of drug from rapidly equilibrating tissues to more slowly equilibrating tissues within the body, whereas the metabolic clearance is a measure of the removal of the drug from the body. The terminal elimination half-life reflects the time for one-half of the drug to be removed from the body. The elimination half-life is governed by the metabolic clearance and the steady-state distribution volume. A high metabolic clearance will decrease the terminal elimination half-life while a large steady-state distribution volume will increase the terminal elimination half-life.
Pharmacodynamic descriptors include the maximal degree of drug effect that can occur (Em~,0 and the steady-state plasma concentration that results in one-half of the maximal effect (ECs0). This latter variable can be used as a measure of tissue sensitivity or responsiveness. An additional pharmacodynamic variable involves the half-time of blood:effect site equilibration. This is a measure of how rapidly the drug moves from plasma into the site of action and will be a major factor in determining the onset of drug effect. To obtain the above pharmacokinetic and pharmacodynamic descriptors, it is necessary to gather both plasma concentration and drug effect data from an individual subject. One then uses the appropriate mathematical models with some form of regression data analysis to derive the pharmacokinetic and dynamic descriptors.
How can pharmaeokinetics and pharmacodynamies improve clinical care?
Pharmacokinetic and pharrnacodynamic information is the scientific basis for the clinical use of drugs in anaesthetic practice. This knowledge can be used in the following ways.
Understanding the clinical drug effect or dose/response relationship within and between drug groups
There are three important clinical drug measures of the effect: the onset, degree of peak effect, and rate of recovery or dissipation of drug effect. Let us use three narcotic drugs (morphine, fentanyl, alfentanil) as art example of integrating the clinical profiles and dose response relationship with pharmacokinetic and dynamic data. The clinical variables are indicated in Table I; Table  II presents the pharmacokinetic variables, while Table III indicates relevant physicochemical properties. Alfentanil has the most rapid onset of narcotic effect while morphine is the slowestfl Physieochemical properties can explain this difference in onset of drug effect. Alfentanil has adequate lipid solubility and a high unionized fraction with a relatively low partitioning or solubility in the brain. Atfentanil can rapidly penetrate the blood:brain barrier and equilibrate with narcotic receptors with minimal non-receptor tissue uptake. Morphine, however, has relatively low lipid-solubility and therefore blood:brain barrier penetration and diffusion to the receptor site is rate-limiting. The peak degree of narcotic effect for these npioids is relatively similar at equipotenl doses, although the time course is very different to achieve this peak effect. As more opioid is given, a more profound degree of narcotic effect can occur to the point of causing complete anaesthesia (Le. high-dose opioids for cardiac surgery). The recovery of narcotic effect for these opioids is dependant on the administered dose. At lower doses, redistribution mechanisms from the brain and spinal cord to other tissues that do not contain opioid receptors is an important mechanism to explain the short duration of narcotic effect. This is especially important for the more-lipophilic compounds (fentanyl, alfentanil) that can rapidly penetrate membrane tissues. Morphine has the lowest and slowest degree of redistribution because of its low lipid solubility and slow membrane transfer. Morphine is removed slowly from its site of action. Recovery of drug effect is also very dependant upon the terminal elimination half-life of the drug. At high doses, fentanyl's duration of narcotic effect approximates morphine because redistribution is no longer present and both nar- 
Characterizing the effect of altered physiological states on drug effect
Pharmacoldnetic and pharmacodynamic concepts can be used to characterize how altered physiological or pharmacological states effect the dose requirement, pharmacokinetics, and pharmacodynamics of anaesthetic drugs. For example, with increasing age, the anaesthetic requirement for thicpental, etomidate, fentanyl and alfentanil decreases, s-7 Lower doses are needed in the elderly, compared with young patients. By measuring EEG dose requirement, plasma concentrations and EEG drug effect in young and old patients, it has been possible to determine that altered distribution pharmacokinetics in the elderly explains in part the decreased dose requirement of the aged for the two inlravenous anaesthetics (thiopentone and etomidate). 5'6 In contrast, fentanyl and alfentanil, demonstrate an enhanced brain sensitivity with increasing age. 7 Distributional pharmacokinetics are not altered for fentanyl and alfentanil in the elderly. Metabolic clearance does decrease with increasing age for alfentanil, but this does not explain the altered dose requirement.
Many other examples are available whereby disease states alter drug pharmacokinetics. In renal failure, the duration of muscle relaxant effect for pancurenium and d-tubocurarine is markedly prolonged. Because of this marked prolongation of drug effect, much lower doses are required to have an acceptable duration of muscle relaxant effect. Pharmacokinetie studies have shown that both pancuranium and d-tubocurarine have a moderate degree of elimination via the kidneys, s'9 Renal failure thus decreases the metabolic clearance and prolongs the terminal elimination half-life. This explains the prolonged duration of drag effect in this clinical situation. In contrast, the two newer relaxants, atracudum and vecuronium, do not have their pharmacokineties altered with renal disease~m'l~ Because of this, it is possible to use these relaxants in comparable doses to normal patients and have an expected and predictable duration of drug effect.
Disease states and age can also change pharmacodynamic relationships. With increasing age, the MAC (minimum alveolar concentration) of potent inhalational anaesthetics decreases, t2 This results from increased brain sensitivity to the inhalational anaesthetics. By understanding how disease alters the drug dose requirement, pharmacokineties and phamlacodynamics, the anaesthetist can more rationally approach an individual patient. By knowing that renal failure markedly prolongs duration of drug effect, one can anticipate this and appropriately change the dosing strategy. In a similar fashion, one can choose drugs whereby the pharmacokinetics and dynamics are not altered by the changed physiological state.
Implementing new approaches to anaesthetic dosing
The two previous subheadings have discussed how pharmacokineties and pharmacodynamics have improved our understanding of traditional approaches to anaesthetic drug administration. It is possible, however, to use pharmacokinetic and pharmacodynamic concepts to actually implement anaesthetic drag dosing. Pharmacodynamic research has defined therapeutic plasma concentrations of fentanyl and alfentanil under various clinical situations. The initial loading dose of a drug is going to be governed by the initial and steady-state distribution volumes. The maintenance infusion rate will be given by the metabolic clearance. The ultimate example of using pharmacodynamics to dose drugs during anaesthesia involves the use of computer-driven pumps driven by pharmacokinetie models.t3 In this situation, the anaesthetist first provides an appropriate pharmacokinetic model and representative kinetic data. After choosing target plasma concentration to be achieved, a computer driven pump then determines the administration rate at frequent (10-to 15-second) intervals needed to achieve these target concentrations. A computer/pump interface is needed for this new drug delivery concept.
Limitations of pharmacokinetics and pharmacodynamics
Pharmacokinetie and pharmacodynamic research is capable of quantitating the relationship between dose, plasma concentration and drug effect for any one individual patient or larger groups of patients. However, this is frequentiy done subsequent to the administration of the drug and anaesthetic because analytical measurement of drug plasma concentrations are generally not available intraoperatively. Additionally, there is a small number of anaesthetic drugs where direct measurement of the drug effect is relevant and practical. Research has established that a moderate degree of variability occurs in patients for both pharrnacokinetie and pharrnacodynamie data. While it is possible to identify factors (i.e., age, weight, sex) that explain some of this variability, it is generally not possible to completely eliminate it. We frequently do not understand why one patient will have a very different degree of response compared to another. This is a clear limitation of pharmacokinetic and pharmacodynamic research. One ultimate goal would be continuous non-invasive measures of the drug effect that are reliable and predictable, similar to the degree of twitch tension for muscle relaxants. If equivalent measures were available for the narcotics, intravenous and inhalational anaesthetics, then all drug administration could be guided by the degree of drug effect with minimal pharmacokinetic considerations, In summary, pharmacokinctic and pharmacodynamic research has many broad implications for anaesthetic can~. Pharmacokinetic and pharmacodynamic information represents the underlying scientific basis for the administration of anaesthetic drugs to patients. Research allows us to understand how and why drug dosage has to be changed in altered physiologic states. Finally, improved methods of drug administration can be performed using kinetic and dynamic concepts. Phannacokinetics and dynamics will, however, never replace the important human components and judgement involved in anaesthetic practice. Because we do not have absolute foolproof measures of anaesthetic drug effect that can be continuously monitored, the anaesthestist's training and judgement will 'always be critical in providing optimal, safe patient care. 
